A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population

NCT ID: NCT05870436

Last Updated: 2023-05-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-19

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a multicenter, open, observational study and was divided into two stages; Stage I study includes patients with suspected asthma to observe the diagnostic value and safety of Methacholine Choline Provocation Test. All patients clinically evaluated for bronchial provocation testing were included in the stage II study to further validate the diagnostic value and cutoff value of the methacholine choline provocation test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a multicenter, open, observational study. The study was divided into two stages; the first stage of the study included a population with suspected asthma and performed a bronchial provocation test, and cumulative provocation dose when forced expiratory volume in one second (FEV1) fell by 20% (PD20 ) data were recorded. Subjects with positive excitation were treated as asthma for 3 months and treatment was considered effective to confirm the diagnosis of asthma. Sensitivity, specificity, and reliability of the methacholine choline provocation test were calculated, and cutoff values were obtained by exploratory analysis based on PD20 values. All patients clinically evaluated for bronchial provocation testing were included in the stage II study to further validate the diagnostic value and cutoff value of the methacholine choline provocation test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive group

The group that conducted the Methacholine Choline Provocation Test with Positive result

Methacholine Choline Provocation Test

Intervention Type DIAGNOSTIC_TEST

Perform methacholine choline provocation test according to the protocol

Negative group

The group that conducted the Methacholine Choline Provocation Test with negative result

Methacholine Choline Provocation Test

Intervention Type DIAGNOSTIC_TEST

Perform methacholine choline provocation test according to the protocol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methacholine Choline Provocation Test

Perform methacholine choline provocation test according to the protocol

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Stage I study:

* clinically evaluated as suspected asthma but have not been previously diagnosed as asthma and require a bronchial provocation test
* Basal lung function FEV1 ≥ 60%
* Meet the requirements for conducting bronchial excitation tests and pulmonary ventilation examinations
* Not currently suffering from or accompanied by other respiratory diseases, including allergic rhinitis, chronic obstructive pulmonary disease, chronic bronchitis, etc.

Stage II study:

* Basal lung function FEV1 ≥ 60%
* Meet the requirements for conducting bronchial excitation tests and pulmonary ventilation examinations

Exclusion Criteria

* Have had a fatal asthma attack, or have required mechanical ventilation for an asthma attack within the last 3 months
* Definite hypersensitivity reaction to inhaled stimulants or salbutamol or unexplained urticaria
* Severe impairment of basal pulmonary ventilation (FEV1 \< 60% of expected value %, or \< 1 L in adults)
* Poor cooperation with basal pulmonary function tests that do not meet quality control requirements
* Other conditions that make a bronchial provocation test or pulmonary ventilation function test inappropriate (e.g., recent presence of severe cardiovascular disease, seizures, uncontrolled hypertension, etc.)
Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

Sponsor Role collaborator

jingping Zheng

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

jingping Zheng

Chief Physician

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

yi Gao, PhD

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Guangzhou Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Chao-yang Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status NOT_YET_RECRUITING

Songshan General Hospital

Chongqing, Chongqing Municipality, China

Site Status NOT_YET_RECRUITING

The First Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Site Status NOT_YET_RECRUITING

Tongji Hospital,Tongji Medical College of Hust

Wuhan, Hubei, China

Site Status NOT_YET_RECRUITING

West China Hospital of Sichuan University

Chengdu, Sichaun, China

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

jingping Zheng

Role: CONTACT

18928868238

yi Gao

Role: CONTACT

13560358322

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

yong Lu, Master

Role: primary

qianli Ma, PhD

Role: primary

jingping Zheng

Role: primary

xiaoju Zhang, PhD

Role: primary

tao Wang, PhD

Role: primary

binmiao Liang, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SX20221101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Phase Ib Study of RC1416 Injection
NCT06911866 RECRUITING PHASE1